<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124556">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02129673</url>
  </required_header>
  <id_info>
    <org_study_id>VS101-CS201</org_study_id>
    <nct_id>NCT02129673</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViSci Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViSci Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Slow release formulation of latanoprost is compared for safety and pressure-lowering
      efficacy with topically administration of commercially available latanoprost in patient with
      glaucoma and ocular hypertension
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intra-ocular pressure</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-ocular pressure</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-ocular pressure</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>VS101 Insert Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VS101 Insert Dose A placed under the conjunctiva</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VS101 Insert Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VS101 Insert Dose B placed under the conjunctiva</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VS101 Insert Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VS101 Insert Dose C placed under the conjunctiva</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost 0.005% eye drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost 0.005% eye drops administered once daily on the eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS101 Insert Dose A</intervention_name>
    <description>Sustained release of latanoprost into the eye</description>
    <arm_group_label>VS101 Insert Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS101 Insert Dose B</intervention_name>
    <description>Sustained release of latanoprost into the eye</description>
    <arm_group_label>VS101 Insert Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS101 Insert Dose C</intervention_name>
    <description>Sustained release of latanoprost into the eye</description>
    <arm_group_label>VS101 Insert Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost 0.005% eye drops</intervention_name>
    <description>Latanoprost 0.005% eye drops administered once daily on the eye</description>
    <arm_group_label>Latanoprost 0.005% eye drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18

          -  Open angle glaucoma or Ocular Hypertension

        Exclusion Criteria:

          -  uncontrolled medical conditions

          -  wearing of contact lenses
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>April 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Intra-ocular pressure</keyword>
  <keyword>Slow Release</keyword>
  <keyword>Controlled release</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
